10.20.17
Johnson & Johnson
3Q Revenues: $19.7 billion (+10%)
3Q Earnings: $3.8 billion (-12%)
YTD Revenues: $56.3 billion (+5%)
YTD Earnings: $12.0 billion (-6%)
Comments: Worldwide Pharmaceutical sales were $9.7 billion in the quarter, up 15%. Domestic sales increased 15% and international sales increased 16%. Remicade sales were $1.6 billion in the quarter, down 8%. Strong growth in new products include DARZALEX ($317 million, up 95%), for the treatment of patients with multiple myeloma and IMBRUVICA ($512 million, up 47%), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. Additional contributors to operational sales growth included STELARA ($1.1 billion, up 38%, a biologic for the treatment of a number of immune-mediated inflammatory diseases, XARELTO ($635 million, up 20%) an oral anticoagulant, ZYTIGA ($669 million, up 15%) an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer and INVEGA SUSTENNA/XEPLION/TRINZA ($643 million, up 16%), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.
3Q Revenues: $19.7 billion (+10%)
3Q Earnings: $3.8 billion (-12%)
YTD Revenues: $56.3 billion (+5%)
YTD Earnings: $12.0 billion (-6%)
Comments: Worldwide Pharmaceutical sales were $9.7 billion in the quarter, up 15%. Domestic sales increased 15% and international sales increased 16%. Remicade sales were $1.6 billion in the quarter, down 8%. Strong growth in new products include DARZALEX ($317 million, up 95%), for the treatment of patients with multiple myeloma and IMBRUVICA ($512 million, up 47%), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. Additional contributors to operational sales growth included STELARA ($1.1 billion, up 38%, a biologic for the treatment of a number of immune-mediated inflammatory diseases, XARELTO ($635 million, up 20%) an oral anticoagulant, ZYTIGA ($669 million, up 15%) an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer and INVEGA SUSTENNA/XEPLION/TRINZA ($643 million, up 16%), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.